Waiakea Decided to Help Others

Waiakea always knew their water was the best. It had to be good since so many people traveled from far away to get a taste of it. The company knew their water was good and they knew a lot of people wanted to drink it. Since they saw it as something people could really enjoy, they wanted others to have the same chance as they did. Waiakea knew others couldn’t buy the water the way they wanted and they knew not everyone could come to Hawaii to taste Waiakea. They decided the best approach was bottling the water so others could try it. Since they knew how to bottle at the source without ever touching the water or compromising anything, they felt it was the best opportunity they had to give people what they were used to drinking. It helped them show people what the water was like and they didn’t even have to come to Hawaii to try it.

Bottling changed things for Waiakea. They knew that they had to reach out and help people understand the importance of their water. Since they made it available to virtually everyone, they could do things other companies were unable to do and that’s how they made sure things would keep getting better for all the people they worked with. It was their goal of helping that allowed them the chance to see things would keep getting better and the bottling company made it possible for more people to try different things.

The opportunities Waiakea had to continue helping people with their water made it easier for them to try different things. They also made sure they were doing everything they could to keep giving back and keep providing positive experiences for everyone who wanted to try Waiakea. The company felt good about bottling and knew it was a great way to branch out. When more people had a chance to try Waiakea, they could get it from the company. They could see the positive experiences that came from using Waiakea and making sure they had everything the right way for the company to take advantage of.


Of Luiz Carlos Trabuco’s Life, Leadership And Succession At Bradesco

Not so many people would have the opportunity to virtually identify with one particular company or institution throughout their career-it’s just very rare. Luiz Carlos Trabuco is one iconic figure to have attained such an accomplishment-working at Bradesco almost the entire time of his employment age.

Luiz Carlos Trabuco’s Bio
Luiz Carlos Trabuco is a graduate from the Faculty of Philosophy, Science, Languages, and Arts, and a post-graduate degree holder in Social Philosophy from the School of Sociology and Politics, University of Sao Paulo.

Joining Bradesco
He joined Bradesco S.A. on 17th April 1969 and became a Departmental Director in 1984 before steadily rising to the rank of Chief Executive Officer since 10th March 2009. Prior to his ascension to the helm, he served as the Executive Vice-President. Elsewhere, he formerly held positions with many companies such as the president of Grupo Segurador.

Besides, he served as the President of the National Association for Private Pension Plans (ANAPP) between August 1994 and August 2000, and a board member of the Brazilian Association for Listed Companies (ABRASCA) between July 2000 and February 2003.

Read more: Bradesco deve anunciar sucessor de Trabuco antes do Carnaval

Succession, an Inevitability
Luiz Carlos Trabuco’s exit from Bradesco’s administration was delayed, in September 2016, following an extension of the maximum age for a CEO’sposition from 65 to 67 years according to istoedinheiro.com.br. Such was a dynamic response to what would have been a hefty undertaking for the bank after the then vice president, and the man to set to succeed Trabuco-Marco Antonio-succumbed to death in a plane crash.

The Leadership Process
Without a doubt, there were high stakes before the grand announcement could be made. Moreover, there was an array of men lined up to take over from Trabuco. On 5th February 2018, the bank officially announced Octavio de Lazari Junior, 54, as its new president. However, Luiz Carlos Trabuco was set to remain in the Council’s Presidency, and in his executive position till an ordinary general meeting would be held in March.

The Future of Banco Bradesco
Lazari, flanked by his predecessors-Lazaro Brandao and Luiz Carlos Trabuco-during in his inaugural speech, outlined his very first challenge was to offer continuity, as well as renewing the legacy of the two. Trabuco confessed it took months to settle on a new president, with Lazari’s merits giving him the cutting edge.

Trabuco’s was a service well rendered while at Bradesco, and peacefully relinquishing the coveted seat when it was time to egress.

For more information about Luiz Carlos Trabuco, just click here.

Clay Siegall: Scientist, Doctor & Futurist

Does the name Clay Siegall sound familiar to you? Have you ever heard of a person with this particular name? The Clay Siegall of this article may be one of the most important persons in cancer research. Why? Clay Siegall, M.D., has helped to revolutionize cancer research via drug development, scientific innovation and rigorous research. He has instilled these key features right into the business and great results have come forth ever since. He also has a heart of gold thanks to his philanthropic nature. The fight against cancer has been waging for decades and decades, but things have gotten much better.

Dr. Siegall is the CEO, the founder and the president for one of the nation’s premier oncology organization. This organization is Seattle Genetics, and it has become a worldwide leader in cancer research. Dr. Siegall, and his team of specialists use some of the most innovative technologies to study this deadly disease. As of now, the organization has up to 20 advanced drugs in its pipeline of success. Four of the twenty drugs could potentially be released within the next few years. Dr. Siegall uses his supreme knowledge to come-up with better solutions to fight this disease. The days of radical surgeries and amputation are far behind us thanks to the advancements in technology.

The FDA-approved drug, ADCETRIS, is the organization’s best-seller. This drug is known as an antibody-drug conjugate. By attaching itself to cancerous cells in the body, it will then go on to deliver its cocktails right into the cancerous cells. One of the best things about this drug is that it won’t leave the patient with sickening effects. Dr. Clay Siegall’s greatness in cancer research can’t be disputed because he has over 30 years of experience, he currently holds at least 15 medical patents, and he has written a plethora of cancer-related publications.